Skip to main content
Top
Published in: Journal of Bioethical Inquiry 1/2020

01-03-2020 | Original Research

Beyond Mendelian Genetics: Anticipatory Biomedical Ethics and Policy Implications for the Use of CRISPR Together with Gene Drive in Humans

Authors: Michael W. Nestor, Richard L. Wilson

Published in: Journal of Bioethical Inquiry | Issue 1/2020

Login to get access

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) genome editing has already reinvented the direction of genetic and stem cell research. For more complex diseases it allows scientists to simultaneously create multiple genetic changes to a single cell. Technologies for correcting multiple mutations in an in vivo system are already in development. On the surface, the advent and use of gene editing technologies is a powerful tool to reduce human suffering by eradicating complex disease that has a genetic etiology. Gene drives are CRISPR mediated alterations to genes that allow them to be passed on to subsequent populations at rates that approach one hundred per cent transmission. Therefore, from an anticipatory biomedical ethics perspective, it is possible to conceive gene drive being used with CRISPR to permanently ameliorate aberrant genes from wild-type populations containing mutations. However, there are also a number of possible side effects that could develop as the result of combining gene editing and gene drive technologies in an effort to eradicate complex diseases. In this paper, we critically analyse the hypothesis that the combination of CRISPR and gene drive will have a deleterious effect on human populations from an ethical perspective by developing an anticipatory ethical analysis of the implications for the use of CRISPR together with gene drive in humans.
Literature
go back to reference Akcakaya, P., M.L. Bobbin, J.A. Guo, et al. 2018. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 561(7723): 416-419.PubMedPubMedCentral Akcakaya, P., M.L. Bobbin, J.A. Guo, et al. 2018. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 561(7723): 416-419.PubMedPubMedCentral
go back to reference Allhoff, F., A. Henschke, and B.J. Strawser. 2016. Binary bullets: the ethics of cyberwarfare. New York: Oxford University Press. Allhoff, F., A. Henschke, and B.J. Strawser. 2016. Binary bullets: the ethics of cyberwarfare. New York: Oxford University Press.
go back to reference Andreasen, N.C. 2008. The relationship between creativity and mood disorders. Dialogues in Clinical Neuroscience 10(2): 251-255.PubMedPubMedCentral Andreasen, N.C. 2008. The relationship between creativity and mood disorders. Dialogues in Clinical Neuroscience 10(2): 251-255.PubMedPubMedCentral
go back to reference Audi, R. 2007. Moral value and human diversity. Oxford University Press. Audi, R. 2007. Moral value and human diversity. Oxford University Press.
go back to reference Babar, M.I., M. Ghazali, D.N. Jawawi, and K. Bin Zaheer. 2015. StakeMeter: vValue-based stakeholder identification and quantification framework for value-based software systems. PLoS One 10(3): e0121344.PubMedPubMedCentral Babar, M.I., M. Ghazali, D.N. Jawawi, and K. Bin Zaheer. 2015. StakeMeter: vValue-based stakeholder identification and quantification framework for value-based software systems. PLoS One 10(3): e0121344.PubMedPubMedCentral
go back to reference Cong, L., F.A. Ran, D. Cox, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121): 819-823.PubMedPubMedCentral Cong, L., F.A. Ran, D. Cox, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121): 819-823.PubMedPubMedCentral
go back to reference Cuilla, J., C. Martin, and R.C. Solomon. 2007. Honest business, a business ethics reader. New York: Oxford University Press. Cuilla, J., C. Martin, and R.C. Solomon. 2007. Honest business, a business ethics reader. New York: Oxford University Press.
go back to reference Esvelt K.M, A.L. Smidler, F. Catteruccia, and G.M. Church. 2014. Concerning RNA-guided gene drives for the alteration of wild populations. Elife, 3. Esvelt K.M, A.L. Smidler, F. Catteruccia, and G.M. Church. 2014. Concerning RNA-guided gene drives for the alteration of wild populations. Elife, 3.
go back to reference Fu, Y., J.A. Foden, C. Khayter, et al. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology 31(9): 822-826.PubMedPubMedCentral Fu, Y., J.A. Foden, C. Khayter, et al. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology 31(9): 822-826.PubMedPubMedCentral
go back to reference Gulati, S. 2008. Technology-enhanced learning in developing nations: A review. The International Review of Research in Open and Distributed Learning 9(1): 1-8. Gulati, S. 2008. Technology-enhanced learning in developing nations: A review. The International Review of Research in Open and Distributed Learning 9(1): 1-8.
go back to reference Hester, K., M. Mullins, F. Murphy, and S.A.M. Tofail. 2015. Anticipatory ethics and governance (AEG): Towards a future care orientation around nanotechnology. NanoEthics 9(2): 123-136. Hester, K., M. Mullins, F. Murphy, and S.A.M. Tofail. 2015. Anticipatory ethics and governance (AEG): Towards a future care orientation around nanotechnology. NanoEthics 9(2): 123-136.
go back to reference Jasanoff, S., and J.B. Hurlbut. 2018. A global observatory for gene editing. Nature 555(7697) 435-437.PubMed Jasanoff, S., and J.B. Hurlbut. 2018. A global observatory for gene editing. Nature 555(7697) 435-437.PubMed
go back to reference Jasanoff, S, J.B. Hurlbut, and K. Saha. 2015. CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology 32(1): 37. Jasanoff, S, J.B. Hurlbut, and K. Saha. 2015. CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology 32(1): 37.
go back to reference Liang, P., Y. Xu, X. Zhang, et al. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5): 363-372.PubMedPubMedCentral Liang, P., Y. Xu, X. Zhang, et al. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5): 363-372.PubMedPubMedCentral
go back to reference Ma, H., N. Marti-Gutierrez., S.W. Park, et al. 2017. Correction of a pathogenic gene mutation in human embryos. Nature 548(7668): 413-419.PubMed Ma, H., N. Marti-Gutierrez., S.W. Park, et al. 2017. Correction of a pathogenic gene mutation in human embryos. Nature 548(7668): 413-419.PubMed
go back to reference Nestor, M.W., E. Artimovich, and R.L. Wilson. 2014. The ethics of gene editing technologies in human stem cells. Ethics in Biology, Engineering and Medicine: An International Journal 5(4): 323-338. Nestor, M.W., E. Artimovich, and R.L. Wilson. 2014. The ethics of gene editing technologies in human stem cells. Ethics in Biology, Engineering and Medicine: An International Journal 5(4): 323-338.
go back to reference Nestor, M.W., and R.L. Wilson. 2018. Can the Use of CRISPR in humans result in decreased social justice for future stakeholders? Ethics in Biology, Engineering and Medicine: An International Journal 9(1): 5-16. Nestor, M.W., and R.L. Wilson. 2018. Can the Use of CRISPR in humans result in decreased social justice for future stakeholders? Ethics in Biology, Engineering and Medicine: An International Journal 9(1): 5-16.
go back to reference Normile, D. 2018. Shock greets claim of CRISPR-edited babies. Science 362(6418): 978-979.PubMed Normile, D. 2018. Shock greets claim of CRISPR-edited babies. Science 362(6418): 978-979.PubMed
go back to reference Oye, K.A., K. Esvelt, E. Appleton, et al. 2014. Biotechnology. Regulating gene drives. Science 345(6197): 626-628.PubMed Oye, K.A., K. Esvelt, E. Appleton, et al. 2014. Biotechnology. Regulating gene drives. Science 345(6197): 626-628.PubMed
go back to reference Polcz, S., and A. Lewis. 2016. CRISPR-Cas9 and the non-germline non-controversy. Journal of Law and the Biosciences 3(2): 413-425. Polcz, S., and A. Lewis. 2016. CRISPR-Cas9 and the non-germline non-controversy. Journal of Law and the Biosciences 3(2): 413-425.
go back to reference Schaefer, K.A.,W.-H. Wu, D.F. Colgan, S.H. Tsang, A.G. Bassuk, and V.B. Mahajan. 2017. Unexpected mutations after CRISPR–Cas9 editing in vivo. Nature Methods 14(6): 547.PubMedPubMedCentral Schaefer, K.A.,W.-H. Wu, D.F. Colgan, S.H. Tsang, A.G. Bassuk, and V.B. Mahajan. 2017. Unexpected mutations after CRISPR–Cas9 editing in vivo. Nature Methods 14(6): 547.PubMedPubMedCentral
go back to reference Schwank, G., B.K. Koo, V. Sasselli, et al. 2013. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13(6): 653-658.PubMed Schwank, G., B.K. Koo, V. Sasselli, et al. 2013. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13(6): 653-658.PubMed
go back to reference Smith, C., L. Abalde-Atristain, C. He, et al. 2015. Efficient and allele-specific genome editing of disease loci in human iPSCs. Molecular Therapy 23(3): 570-577.PubMed Smith, C., L. Abalde-Atristain, C. He, et al. 2015. Efficient and allele-specific genome editing of disease loci in human iPSCs. Molecular Therapy 23(3): 570-577.PubMed
go back to reference Sun, N., and H. Zhao. 2014. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnology and Bioengineering 111(5): 1048-1053.PubMed Sun, N., and H. Zhao. 2014. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnology and Bioengineering 111(5): 1048-1053.PubMed
go back to reference Wang, H., M. La Russa, and L.S. Qi. 2016. CRISPR/Cas9 in genome editing and beyond. Annual Review of Biochemistry 85: 227-264.PubMed Wang, H., M. La Russa, and L.S. Qi. 2016. CRISPR/Cas9 in genome editing and beyond. Annual Review of Biochemistry 85: 227-264.PubMed
go back to reference Werhane, P.H. 2002. Moral imagination and systems thinking. Journal of Business Ethics 38(1-2): 33-42. Werhane, P.H. 2002. Moral imagination and systems thinking. Journal of Business Ethics 38(1-2): 33-42.
go back to reference Xie, F., L. Ye, J.C. Chang, et al. 2014. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Research 24(9): 1526-1533.PubMedPubMedCentral Xie, F., L. Ye, J.C. Chang, et al. 2014. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Research 24(9): 1526-1533.PubMedPubMedCentral
go back to reference Yin, H., W. Xue, S. Chen, et al. 2014. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology 32(6): 551-553.PubMedPubMedCentral Yin, H., W. Xue, S. Chen, et al. 2014. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology 32(6): 551-553.PubMedPubMedCentral
Metadata
Title
Beyond Mendelian Genetics: Anticipatory Biomedical Ethics and Policy Implications for the Use of CRISPR Together with Gene Drive in Humans
Authors
Michael W. Nestor
Richard L. Wilson
Publication date
01-03-2020
Publisher
Springer Singapore
Published in
Journal of Bioethical Inquiry / Issue 1/2020
Print ISSN: 1176-7529
Electronic ISSN: 1872-4353
DOI
https://doi.org/10.1007/s11673-019-09957-7

Other articles of this Issue 1/2020

Journal of Bioethical Inquiry 1/2020 Go to the issue